相关实验视频

Updated: Jul 1, 2025

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

使用小分子,TAK-242抑制托尔类受体4保护岛屿免受先天免疫反应

Jordan Mattke¹, Carly M Darden², Srividya Vasu³

¹Institute of Biomedical Studies, Baylor University, Waco, TX 76706, USA.

|March 13, 2024

概括

使用TAK-242向通类受体4 (TLR4) 会降低移植后的先天免疫反应和小岛损伤. 这种方法有望改善糖尿病患者的小岛移植成功率.

科学领域:

免疫学免疫学免疫学
内分泌学在内分泌学.
移植移植移植移植

背景情况:

1型和3c型糖尿病涉及胰腺β细胞质量的损失.
岛屿移植是一种恢复β细胞功能的治疗策略.
天生的免疫反应,包括即时的血液介导炎症反应和单细胞激活,有助于移植的岛屿损失.

研究的目的:

为了研究收费类受体4 (TLR4) 在岛屿移植后先天性炎症反应中的作用.
评估针对TLR4的有效性,以减轻岛屿损伤和免疫细胞激活.

主要方法:

对血生物标志物 (miR-375,miR-200c) 的评估,以评估移植功能损失.
在体外模型研究TLR4抑制对小岛细胞和免疫细胞的影响.
在周周移植模型中使用TLR4抑制剂TAK-242.

主要成果:

移植后不久观察到移植功能丧失,由生物标志物变化表明.
用TAK-242准TLR4在体外证明可以减轻小岛的损伤.
在周周移植期间,TAK-242降低了免疫细胞的激活.

结论:

托尔类受体4 (TLR4) 抑制是一种可行的策略,可以减少岛屿移植后的先天免疫反应和炎症.
TAK-242显示出作为治疗剂的潜力,可以改善岛屿移植的结果.
准TLR4可能会提高糖尿病患者岛屿移植的长期成功.

关键词:

在 TLR4 中,这是一种炎症炎症炎症炎症.即时通过血液介导的炎症反应.这是一个小RNARNA.整体胰腺切除术与小岛自身移植.

更多相关视频

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...